400 million anti-tumor injections Zheng Daqing will welcome the first review.

Recently, Nanjing Zhengda Qing's injection of hydrochloric acid Idabi Star (acceptance number CYHS1900246, CYHS1900247) imitation 4 categories of listing applications into the administrative approval stage, is expected to be approved in the near future and the first evaluation. according to
, sales of Ida Bixing, a public medical institution terminal in China, in 2019 were 391 million yuan, up 10.69 percent year-on-year.
injection of Idabiton hydrochloric acid is an anti-systic and cytotoxic agent used in the first-line treatment of acute non-lymphocytic leukemia (ANLL) in adults, as well as induced remission therapy in patients with relapse and difficult treatment.
the only domestic approved manufacturers of the product are Pfizer and Hanyu Pharmaceuticals. according to
,
, the sales of Ida Bixing, the terminal of China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions), were 391 million yuan in 2019, up 10.69 percent year-on-year.
, Hanyu Pharmaceuticals has a market share of 56.16 percent and Pfizer 43.84 percent.
China's public medical institutions terminal injection of hydrochloric acid Idabi star sales (units: 10,000 yuan) 2019 China's public medical institutions terminal injection with hydrochloric acid Idabi star manufacturers competition pattern of the inner net consistency evaluation database shows that the injection of hydrochloric acid Idabi star has not yet been approved by enterprises through consistency evaluation.
Nanjing Zhengda Qing's injection hydrochloric acid Idabi star registration status has been changed to "in approval", after approval will become the first approved enterprise of the variety.
source: Minnet.com.